Jenoptik (JEN) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
15 Jan, 2026Executive summary
Revenue and operating profit for the first nine months of 2024 developed in line with expectations, with revenue up 6.0% to €815.1m and EBITDA up 12.2% to €160.6m, supported by strong order backlog and robust execution across divisions.
Earnings per share rose 22.3% to €1.15; order intake declined 6.4% to €781.9m, mainly due to weak automotive demand and a prior-year major order.
Strategic midterm targets of €1.2bn in sales and 21–22% EBITDA margin postponed by one year to 2026, with 2025 expected to be a transition year.
Long-term growth prospects remain intact despite current market uncertainties and delays in the semiconductor upturn.
Order backlog remained robust at €709.2m, down 4.8% from year-end 2023.
Financial highlights
Revenue grew organically by 6% year-over-year to €815.1m, driven by Advanced Photonic Solutions and NPC segments.
Group EBITDA reached €160.6m, margin up to 19.7% from 18.6% year-over-year.
Earnings per share increased by 22.3% to €1.15; gross margin at 33.9%, down from 34.7% year-over-year.
Free cash flow before interest and tax payments up 9.6% to €62.3m; net debt at €421.4m; leverage at 1.9x EBITDA.
EBIT up 18.6% to €104.6m; EBIT margin at 12.8% (prior year: 11.5%).
Outlook and guidance
2024 revenue and profit guidance reaffirmed, expecting mid-single-digit revenue growth and EBITDA margin between 19.5% and 20%, including a 0.5pp negative impact from the Dresden move.
2025 financial targets postponed to 2026, now expecting €1.2bn revenue and 21–22% EBITDA margin.
Order intake for the year is expected to be slightly below the prior year; CapEx will be slightly higher.
No guidance for 2025 yet; 2025 is seen as a transition year with stable or slightly growing topline, but below original expectations.
Ramp-up of the Dresden facility and full capacity utilization delayed in line with postponed semiconductor market upturn.
Latest events from Jenoptik
- Revenue and earnings up, 2024 guidance confirmed amid robust semiconductor demand.JEN
Q2 20241 Feb 2026 - Revenue and profit fell in H1 2025, with guidance cut amid ongoing global uncertainties.JEN
Q2 20256 Jan 2026 - 2024 saw strong growth and margins, but 2025 outlook is cautious amid persistent uncertainties.JEN
Q4 20243 Dec 2025 - Revenue and EBITDA fell, but free cash flow and order intake improved amid market uncertainty.JEN
Q3 202512 Nov 2025 - Revenue and profit fell, but Biophotonics and cash flow improved; outlook remains cautious.JEN
Q1 20256 Jun 2025 - Record revenue and EBITDA in 2024, led by semiconductor growth, despite market headwinds.JEN
Q4 2024 TU5 Jun 2025